TD Cowen analyst Phil Nadeau has maintained their bullish stance on VYGR stock, giving a Buy rating yesterday.
Phil Nadeau has given his Buy rating due to a combination of factors related to Voyager Therapeutics’ promising financial and developmental outlook. The company reported a strong cash position of $295 million, which is expected to support operations until mid-2027, providing a solid financial foundation for its ongoing and future projects.
Voyager Therapeutics is making significant progress in its pipeline, particularly in its Alzheimer’s disease programs. The ongoing dosing in the VY7523 trial and the expected proof-of-concept data in 2026 are key milestones. Additionally, the collaboration with Neurocrine Biosciences on the GBA1 and FXN programs, with INDs anticipated in 2025, further strengthens Voyager’s developmental prospects. These factors collectively contribute to the positive outlook and justify the Buy rating.
In another report released yesterday, Wedbush also reiterated a Buy rating on the stock with a $9.00 price target.
Based on the recent corporate insider activity of 20 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of VYGR in relation to earlier this year.